[1]王颖,陈任安,李国辉,等.化疗联合微移植诱导治疗难治及复发急性髓系白血病疗效观察[J].第三军医大学学报,2016,38(12):1347-1349.
 Wang Ying,Chen Ren&rsquo,an,et al.Efficacy of micro transplantation induction combined with chemotherapy for refractory and relapsed acute myeloid leukemia[J].J Third Mil Med Univ,2016,38(12):1347-1349.
点击复制

化疗联合微移植诱导治疗难治及复发急性髓系白血病疗效观察(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
38卷
期数:
2016年第12期
页码:
1347-1349
栏目:
专题报道
出版日期:
2016-06-30

文章信息/Info

Title:
Efficacy of micro transplantation induction combined with chemotherapy for refractory and relapsed acute myeloid leukemia
作者:
王颖陈任安李国辉尹郸丹赵辉及月茹亓晖陈怡付伟刘利
第四军医大学唐都医院血液内科
Author(s):
Wang Ying Chen Ren’an Li Guohui Yin Dandan Zhao Hui Ji Yueru Qi Hui Chen Yi Fu Wei Liu Li

Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi Province, 710038, China

关键词:
急性髓系白血病难治复发微移植
Keywords:
acute myeloid leukemia refractory relapsed micro transplantation
分类号:
R617; R730.53; R733.71
文献标志码:
A
摘要:

目的      研究化疗联合微移植方案治疗难治及复发急性髓系白血病(acute myeloid leukemia,AML)的疗效。      方法      收集2014年2-8月在唐都医院血液内科采用化疗联合微移植方案诱导治疗的12例难治及复发急性髓系白血病患者,对治疗效果进行分析。      结果      12例患者均完成1个疗程的化疗联合微移植,其中获得完全缓解3例,部分缓解3例,未缓解6例,有效率50%。达到完全缓解的3例中2例随后分别行二次微移植、异基因骨髓移植治疗,1例患者在第1次微移植后1个月时出现移植物抗宿主病(GVHD)导致死亡。部分缓解3例中2例行二次微移植治疗,仍未缓解,1例放弃治疗。6例未缓解中2例分别行二次微移植、异基因骨髓移植结果均未缓解,2例因并发症于院外死亡,2例放弃治疗。      结论      化疗联合微移植提高了难治、复发ANLL的缓解率,并且降低单纯化疗的毒性作用,是难治复发ANLL的较好的治疗手段。

Abstract:

Objective      To determine the efficacy of micro transplantation induction combined with chemotherapy for refractory and relapsed acute myeloid leukemia (AML).       Methods      Totally 12 refractory and relapsed AML patients who were treated with chemotherapy and micro transplantation in our department from February to August 2014 were enrolled in this study, and their outcomes were analyzed.       Results      All the patients had finished 1 course of treatment, and among them, 3 patients achieved complete remission (CR), 3 partial remission (PR), while the other 6 patients non-remission (NR) to our treatment. Two CR patients then received a second micro transplantation and allogeneic bone marrow transplantation (allo-BMT), and the other 1 died of GVHD in 1 month after first micro transplantation. The 2 PR patients also experienced a second micro transplantation, but both had no effect, and the other gave up the treatment at last. Of the 6 NR patients, 1 patient received a second course of micro transplantation and 1 patient received allo-BMT, but the results remained the same, still NR. The other 2 patients died of complications, and the left 2 patients gave up the treatment.       Conclusion      Micro transplantation and chemotherapy elevates the remission rate in the treatment of refractory and relapsed AML and reduces the toxicity of chemotherapy, and is a good treatment for AML.

参考文献/References:

[1]张之南, 沈悌. 血液病诊断及疗效标准[M]. 3版. 北京: 科学出版社, 2007: 107-108, 131-132.
[2]CTCAE v4.0, Common Termonology Criteria for Adverse Events [EB/OL]. [2011/09/01]http: //www.calgb.org/public/ meetings/presentations/2009/summer_group/cra_cont_ed/06a_CTCAE-Setser_062009.pdf.
[3]Chang Y J, Wang Y, Huang X J. Haploidentical stem cell transplantation for the treatment of leukemia: current status[J]. Expert Rev Hematol, 2014, 7(5): 635-647. DOI: 10.1586/ 17474086.2014.954543
[4]Keating M J, Kantarjian H, Smith T L, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia[J]. J Clin Oncol, 1989, 7(8): 1071-1080.
[5]Guo M, Hu K X, Yu C L, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients[J]. Blood, 2011, 117(3): 936-941. DOI: 10.1182/blood-2010-06-288506
[6]Lowenberg B, Downing J R, Burnett A. Acute myeloid leukemia[J]. N Engl J Med, 1999, 341(14): 1051-1062. DOI: 10.1056/nejm199909303411407
[7]Lee S, Tallman M S, Oken M M, et al. Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Eastern Cooperative Oncology Group[J]. Leukemia, 2000, 14(8): 1345-1348.
[8]Guo M, Hu K X, Liu G X, et al. HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up[J]. J Clin Oncol, 2012, 30(33): 4084-4090. DOI: 10.1200/JCO.2012.42.0281

更新日期/Last Update: 2016-06-07